Cite
Melphalan/Prednisone/Lenalidomide (MPR) Versus High-Dose Melphalan and Autologous Transplantation (MEL200) in Newly Diagnosed Multiple Myeloma (MM) Patients <65 Years: Results of a Randomized Phase III Study
MLA
Palumbo, Antonio, et al. Melphalan/Prednisone/Lenalidomide (MPR) Versus High-Dose Melphalan and Autologous Transplantation (MEL200) in Newly Diagnosed Multiple Myeloma (MM) Patients <65 Years: Results of a Randomized Phase III Study. Jan. 2011. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.od.......970..a1928c06f7b702c931b8f09b0c34d1f6&authtype=sso&custid=ns315887.
APA
Palumbo, A., Cavallo, F., Hardan, I., Lupo, B., Redoglia, V., Levin, M., Corradini, P., Pezzatti, S., Patriarca, F., Cavo, M., Marcatti, M., Pescosta, N., Falcone, A., Ria, R., Rossi, D., Benevolo, G., Cangialosi, C., Galli, M., Catalano, L., … Boccadoro, M. (2011). Melphalan/Prednisone/Lenalidomide (MPR) Versus High-Dose Melphalan and Autologous Transplantation (MEL200) in Newly Diagnosed Multiple Myeloma (MM) Patients <65 Years: Results of a Randomized Phase III Study.
Chicago
Palumbo, Antonio, Federica Cavallo, I Hardan, B Lupo, V Redoglia, M Levin, P Corradini, et al. 2011. “Melphalan/Prednisone/Lenalidomide (MPR) Versus High-Dose Melphalan and Autologous Transplantation (MEL200) in Newly Diagnosed Multiple Myeloma (MM) Patients <65 Years: Results of a Randomized Phase III Study,” January. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.od.......970..a1928c06f7b702c931b8f09b0c34d1f6&authtype=sso&custid=ns315887.